Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Dementia Complex | 5 | 2025 | 116 | 1.730 |
Why?
|
| Angiotensin II | 4 | 2021 | 102 | 1.540 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2017 | 23 | 0.900 |
Why?
|
| Monocytes | 3 | 2025 | 277 | 0.850 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 25 | 0.820 |
Why?
|
| Exosomes | 1 | 2025 | 126 | 0.780 |
Why?
|
| Myocytes, Cardiac | 2 | 2017 | 183 | 0.700 |
Why?
|
| Neuroblastoma | 1 | 2021 | 136 | 0.650 |
Why?
|
| Flow Cytometry | 5 | 2017 | 411 | 0.650 |
Why?
|
| Losartan | 2 | 2017 | 35 | 0.610 |
Why?
|
| Heart | 2 | 2012 | 184 | 0.600 |
Why?
|
| Plasmodium berghei | 2 | 2024 | 34 | 0.560 |
Why?
|
| HIV Infections | 3 | 2025 | 2586 | 0.530 |
Why?
|
| Pharmacology | 1 | 2017 | 6 | 0.530 |
Why?
|
| Immunoassay | 1 | 2017 | 74 | 0.490 |
Why?
|
| Glucose | 1 | 2017 | 244 | 0.470 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 280 | 0.460 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 465 | 0.430 |
Why?
|
| Cognition Disorders | 1 | 2015 | 243 | 0.390 |
Why?
|
| Fumarates | 1 | 2012 | 11 | 0.380 |
Why?
|
| Insulin Resistance | 1 | 2015 | 201 | 0.380 |
Why?
|
| Electrophysiological Phenomena | 1 | 2012 | 20 | 0.380 |
Why?
|
| Malaria | 2 | 2024 | 90 | 0.380 |
Why?
|
| Receptor, Angiotensin, Type 1 | 4 | 2017 | 30 | 0.370 |
Why?
|
| Amides | 1 | 2012 | 71 | 0.370 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 61 | 0.360 |
Why?
|
| Parasitemia | 1 | 2011 | 13 | 0.350 |
Why?
|
| Staining and Labeling | 1 | 2011 | 107 | 0.340 |
Why?
|
| Erythrocytes | 1 | 2011 | 126 | 0.330 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 182 | 0.320 |
Why?
|
| Angiotensinogen | 1 | 2009 | 6 | 0.300 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2009 | 9 | 0.300 |
Why?
|
| Renin | 1 | 2009 | 26 | 0.300 |
Why?
|
| Blood Pressure | 1 | 2012 | 666 | 0.290 |
Why?
|
| Renin-Angiotensin System | 1 | 2008 | 48 | 0.280 |
Why?
|
| Spironolactone | 1 | 2008 | 36 | 0.270 |
Why?
|
| Cathepsin B | 2 | 2022 | 35 | 0.270 |
Why?
|
| Calcium Signaling | 1 | 2008 | 107 | 0.260 |
Why?
|
| HIV-1 | 3 | 2025 | 755 | 0.240 |
Why?
|
| Receptors, IgG | 1 | 2025 | 53 | 0.220 |
Why?
|
| Heart Failure | 1 | 2008 | 302 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 458 | 0.210 |
Why?
|
| Hydrazones | 1 | 2024 | 11 | 0.210 |
Why?
|
| Animals | 9 | 2024 | 16992 | 0.210 |
Why?
|
| Antimalarials | 1 | 2024 | 64 | 0.200 |
Why?
|
| Drug Synergism | 1 | 2024 | 195 | 0.200 |
Why?
|
| Humans | 12 | 2025 | 43102 | 0.190 |
Why?
|
| Plasmodium falciparum | 1 | 2024 | 144 | 0.190 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2022 | 38 | 0.180 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 196 | 0.170 |
Why?
|
| Cannabinoids | 1 | 2022 | 73 | 0.170 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2021 | 95 | 0.160 |
Why?
|
| Female | 9 | 2025 | 24698 | 0.160 |
Why?
|
| Hypertension | 2 | 2017 | 835 | 0.160 |
Why?
|
| Middle Aged | 4 | 2025 | 12222 | 0.150 |
Why?
|
| Adult | 5 | 2025 | 13872 | 0.150 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2009 | 41 | 0.140 |
Why?
|
| Cricetinae | 2 | 2009 | 241 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 532 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2021 | 638 | 0.140 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 65 | 0.140 |
Why?
|
| Macrophages | 1 | 2022 | 529 | 0.130 |
Why?
|
| Rats | 2 | 2017 | 3735 | 0.130 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 25 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2017 | 121 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2017 | 50 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2015 | 2544 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 139 | 0.120 |
Why?
|
| Catechin | 1 | 2016 | 39 | 0.120 |
Why?
|
| Stilbenes | 1 | 2016 | 44 | 0.120 |
Why?
|
| Quercetin | 1 | 2016 | 46 | 0.120 |
Why?
|
| Breast | 1 | 2016 | 139 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 3156 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 1723 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 28 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 134 | 0.110 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 284 | 0.110 |
Why?
|
| Cell Line | 1 | 2017 | 1410 | 0.100 |
Why?
|
| Cystatin B | 1 | 2013 | 11 | 0.100 |
Why?
|
| Disease Progression | 2 | 2013 | 667 | 0.100 |
Why?
|
| Rats, Transgenic | 1 | 2012 | 34 | 0.100 |
Why?
|
| Systole | 1 | 2012 | 67 | 0.100 |
Why?
|
| Puerto Rico | 1 | 2017 | 1413 | 0.090 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 164 | 0.090 |
Why?
|
| Fibrosis | 1 | 2012 | 169 | 0.090 |
Why?
|
| Bisbenzimidazole | 1 | 2011 | 2 | 0.090 |
Why?
|
| Propidium | 1 | 2011 | 20 | 0.090 |
Why?
|
| Rhodamines | 1 | 2011 | 22 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2012 | 123 | 0.090 |
Why?
|
| Ribonucleases | 1 | 2011 | 32 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2012 | 185 | 0.090 |
Why?
|
| Limit of Detection | 1 | 2011 | 94 | 0.090 |
Why?
|
| Fluorescence | 1 | 2011 | 118 | 0.090 |
Why?
|
| Action Potentials | 1 | 2012 | 246 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 209 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2012 | 341 | 0.080 |
Why?
|
| Myocardium | 1 | 2012 | 263 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2017 | 2157 | 0.080 |
Why?
|
| Mice | 3 | 2024 | 6644 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 719 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1124 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 665 | 0.070 |
Why?
|
| Proteome | 1 | 2010 | 152 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2012 | 986 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1019 | 0.070 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2008 | 15 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 256 | 0.070 |
Why?
|
| Aldosterone | 1 | 2008 | 66 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2008 | 98 | 0.070 |
Why?
|
| Antioxidants | 1 | 2010 | 443 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 237 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2009 | 1621 | 0.060 |
Why?
|
| Male | 3 | 2024 | 23409 | 0.060 |
Why?
|
| Plasmodium cynomolgi | 1 | 2024 | 4 | 0.050 |
Why?
|
| Plasmodium vivax | 1 | 2024 | 8 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2024 | 63 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1455 | 0.040 |
Why?
|
| Virus Replication | 1 | 2022 | 318 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 2676 | 0.040 |
Why?
|
| Carbazoles | 1 | 2017 | 49 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2017 | 139 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 158 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 68 | 0.030 |
Why?
|
| Vitis | 1 | 2016 | 37 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 408 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 346 | 0.030 |
Why?
|
| Neurons | 1 | 2022 | 1263 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 299 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1568 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 945 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 655 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 348 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2013 | 173 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 2010 | 12 | 0.020 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 11 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 68 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 57 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 64 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2010 | 41 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 536 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1063 | 0.020 |
Why?
|
| United States | 1 | 2013 | 5205 | 0.010 |
Why?
|